Published in the British Medical Journal on January 18, 2020, a review of six randomized controlled trials (RCTs) found that cannabinoids were no different from placebos when it came to changing patients’ average pain levels. The trials examined the effects of cannabinoid extracts, such as Sativex, rather than flower-based medicinal cannabis. Sativex (Nabiximols) is a combination drug standardized in composition, formulation, and dose. Its principal active cannabinoid components are the cannabinoids: tetrahydrocannabinol (THC) and cannabidiol (CBD). Each spray delivers a dose of 2.7 mg THC and 2.5 mg CBD. Sativex was developed by the UK company GW Pharmaceuticals. We can draw our conclusions on what would have happened if they had used flower extracts rather than a GW Pharma creation. Thoughts? Study: https://spcare.bmj.com/content/early/2020/01/08/bmjspcare-2019-002032 Source (@analyticalcannabis) https://www.analyticalcannabis.com/articles/cannabis-extracts-dont-effectively-relieve-cancer-pain-review-finds-312207 #cbdstudies #cbdheals #cbdnews #cannaeducation #cannanews #hempnews #england #sativex #sativexiscannabis #cannabis #cancer #cancerpain #cancertreatments #cancersucks #painrelief #painmanagement #painfree #cancersurvivor #cannabinoid #cannabinoidresearch #cbdresearch #cannabisresearch #cannabisstudy #cbdstudy (at England) https://www.instagram.com/p/B7rJ6n0BorH/?igshid=1wz9vd68snjl4